Figure 1




Compound No.	Structure
1	AGP-2575
2	AGP-1252
3	 venetoclax (ABT-199)
4	 navitoclax (ABT-263)
5	 (S55746/BCL201)
6	S65487
7	BGB-11417
8	FCN-338
9	AZD0466

Figure 2







Compound No.	Structure
1A	
2A	
3A	
4A	
5A	
6A	

Figure 2 (cont.)








Compound No.	Structure
7A	
8A	
9A	
10A	
11A	
12A	

Figure 3


DMS-53
% Inhibition
100
80
60
40
20
0
Compound 1a
Compound 3
Compound 1a + 3



Vehicle A
Compound 1a 60 mg/kg po qd x21
Compound 3 25 mg/kg po qd x21
Compound 3 25 mg/kg + Compound 1a 60 mg/kg po qd x21
Tumor Volume (mm³)
2400
2000
1600
1200
800
400
0
-1
1
3
5
7
9
11
13
15
17
19
21
23
Days Post Treatment

Figure 4